Quynh-Thu Le
Publication Details
-
An international collaboration to harmonize the quantitative plasma epstein-barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma.
Clin Cancer Res. 2013; (8): 2208-15
Persistently elevated posttreatment plasma EBV DNA is a robust predictor of relapse in nasopharyngeal carcinoma (NPC). However, assay standardization is necessary for use in biomarker-driven trials. We conducted a study to harmonize the method between four centers with expertise in EBV DNA quantitation.
Help
Trial Administration